Single-chain antibodies as diagnostic tools and therapeutic agents.

نویسندگان

  • Christoph E Hagemeyer
  • Constantin von Zur Muhlen
  • Dominik von Elverfeldt
  • Karlheinz Peter
چکیده

Over three decades after the generation of the first mouse monoclonal antibodies by Kohler and Milstein, recombinant antibodies are the fastest growing class of therapeutic proteins. Furthermore, antibodies are key detection reagents in research and diagnostics. Technology improvements have provided several approaches to manufacturing human antibodies with high affinity for biologically relevant targets. Approximately 300 development programs for therapeutic antibodies have been reported in industrial and academic laboratories, and this clearly demonstrates the expectations towards antibody technology. Antibody fragments are a subclass with growing clinical importance. This review focuses on single-chain antibodies as one of the smallest possible format for recombinant antibodies and their use as diagnostic tools and therapeutic agents. We describe the structure, selection and production of single-chain antibodies. Furthermore, we review current applications of antibody fragments focusing on thrombus targeting using fibrin- and platelet-specific single-chain antibodies as well as describing novel noninvasive imaging approaches for the diagnosis of thrombosis and inflammation.

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Targeted Cancer Diagnostic and Therapeutic Agents: Delivery by Carriers or Conjugation

Receptors and proteins are overexpressed in many human cancer cell membranes rather than normal tissues and are considered as the main molecular targets. Specific tumor- targeting molecules which have high affinity for these receptors can be valuable tools as carrier molecules for targeted cancer therapy and imaging. Pharmacokinetics and bioavailability of diagnostic and therapeutic agents are ...

متن کامل

Monoclonal Antibodies as Therapeutic Agents: Advances and Challenges

Despite the major advances in conventional forms of treatment (i.e. surgical techniques, radiotherapy and chemotherapy) and improved survival rates, cancer is still the second leading cause of death in developing countries. One major limitation of cytotoxic drugs and radiation in the treatment of cancer patients is their inability to discriminate between malignant and normal tissues. This in tu...

متن کامل

Recombinant scFv Antibodies against P30 Surface Protein of Toxoplasma Gondii

Background & Aims: Toxoplasma gondii is an obligate, intracellular parasite, which is widely spread in the world. The parasite is able to infect all warm-blooded hosts including humans and farm animals. The infection in humans often occurs after the ingestion of raw or undercooked meat containing tissue cysts. Several methods have been applied to detect this parasite in contaminated foods. Reco...

متن کامل

نانوبادی و کاربردهای درمانی آن

Background and purpose: Monoclonal antibodies market has grown since approval of Muromonab-CD3 (trade name Orthoclone OKT3) in 1986 as immuno- suppressor. Nevertheless, the undesirable effects of these large specific biomolecules calls for further attempts for more effective alternatives. Variable domain of heavy chain (VHH) are the smallest antibody fragments called Nanobody (Nb), derived...

متن کامل

مروری بر تولید و کاربرد آنتی بادی های منوکلونال تک زنجیره ای: scFv

Abstract Background: Since the development of monoclonal antibodies by hybridoma technology the use of antibodies in targeted therapy has been considered. ScFv (single-chain variable fragment) is a small fragment of monoclonal antibody which binds to its target, especially. The goal of this study, is introducing of scFv, its production pathways as well as its diagnostic and therapeutic appl...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

عنوان ژورنال:
  • Thrombosis and haemostasis

دوره 101 6  شماره 

صفحات  -

تاریخ انتشار 2009